Drug Profile
Research programme: bone morphogenetic protein receptor agonists - Thrasos Therapeutics
Alternative Names: AA 123; AA 166; AA 204; THR 575; THR-123; THR-166; THR-C; THR-V-123Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Thrasos Therapeutics
- Class Peptides; Small molecules
- Mechanism of Action Bone morphogenetic protein receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Kidney disorders
Highest Development Phases
- No development reported Breast cancer; Cartilage disorders; Kidney disorders; Obesity; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders(Prevention) in USA
- 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in USA